Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Swapna Johncy"'
Autor:
Swapna Johncy
Publikováno v:
Athens Journal of Health and Medical Sciences, Vol 9, Iss 1, Pp 39-48 (2022)
Immunotherapy is a type of treatment that improves an individual’s ability to detect and attack cancerous tissues. The main objective of adopting immunotherapy in cancer treatment is to improve the patient’s quality of life (QoL). To address the
Externí odkaz:
https://doaj.org/article/7bb5bdb470824ff9a7361d15e930cdaa
Publikováno v:
Athens Journal of Health and Medical Sciences, Vol 9, Iss 1, Pp 49-70 (2022)
Children experience high levels of anxiety before surgery. Preoperative anxiety interferes with anesthesia induction compliance and is associated with many short and long-term postoperative complications The aim of this integrative review was to eval
Externí odkaz:
https://doaj.org/article/ec79e36152da4cebb9f5b106d6cc69f7
Autor:
Paolo Strati, Ankur Varma, Sherry Adkins, Loretta J. Nastoupil, Jason Westin, Fredrick B. Hagemeister, Nathan H. Fowler, Hun J. Lee, Luis E. Fayad, Felipe Samaniego, Sairah Ahmed, Yiming Chen, Sandra Horowitz, Sara Arafat, Swapna Johncy, Partow Kebriaei, Victor Eduardo Mulanovich, Ella Ariza Heredia, Sattva S. Neelapu
Publikováno v:
Haematologica, Vol 106, Iss 10 (2020)
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 may be associated with long-term adverse effects such as cytopenia and immune deficiency. In order to characterize these late events, we analyzed 31 patients with relapsed or refractory la
Externí odkaz:
https://doaj.org/article/58088487f8c942138e28d376e4588649
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has significantly improved the outlook for many patients with relapsed and/or refractory B-cell malignancies. The use of CAR T-cell therapy and other therapeutic immune effector cel
Externí odkaz:
https://doaj.org/article/fdc3d6c1b285470699cabcc1a72c160b
Autor:
Hun Ju Lee, Swapna Johncy, Sattva S. Neelapu, Misha Hawkins, Sandra B. Horowitz, Partow Kebriaei, Ranjit Nair, Jason R. Westin, Lei Feng, Haleigh Mistry, Catherine M. Claussen, Sherry Adkins, Sairah Ahmed, Loretta J. Nastoupil, Swaminathan Padmanabhan Iyer, Nicole Johnson, Michael Wang, Fateeha Furqan, Paolo Strati, Ryan Sun, Raphael E Steiner, Felipe Samaniego, Christopher R. Flowers, Prachee Singh, Michael R. Green, Chelsea C. Pinnix, Simrit Parmar, Luis Fayad, Elizabeth J. Shpall, Maria A Rodriguez
Publikováno v:
Blood
Corticosteroids are used to treat the acute complications of chimeric antigen receptor (CAR) T-cell therapy. Strati et al examine the impact of corticosteroids on patient outcomes following CAR T-cell therapy for large B-cell lymphoma. Use of higher
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology
Frontiers in Oncology
Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has significantly improved the outlook for many patients with relapsed and/or refractory B-cell malignancies. The use of CAR T-cell therapy and other therapeutic immune effector cel
Autor:
S.S. Neelapu, Fredrick B. Hagemeister, Nathan Fowler, Ankur Varma, Swapna Johncy, Sara Arafat, Sherry Adkins, Jason R. Westin, Paolo Strati, Felipe Samaniego, Partow Kebriaei, L. J. Nastoupil, Salmaan Ahmed, E. Ariza Heredia, Luis Fayad, Hun J. Lee, Victor E. Mulanovich
Publikováno v:
Hematological Oncology. 37:311-312
Autor:
Partow Kebriaei, Loretta J. Nastoupil, Sattva S. Neelapu, Paolo Strati, Felipe Samaniego, Sherry Adkins, Fredrick B. Hagemeister, Nathan Fowler, Victor E. Mulanovich, Ankur Varma, Sairah Ahmed, Sara Arafat, Jason R. Westin, Hun Ju Lee, Swapna Johncy, Luis Fayad, Ella J. Ariza-Heredia
Publikováno v:
Journal of Clinical Oncology. 37:7545-7545
7545 Background: Cytopenia lasting beyond 30 days has been observed after CAR T cell therapy. Here, we describe the hematopoietic recovery and immune reconstitution following axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory larg